Analyst Consensus ?
ConsensusBuy24 ratings
Bullish1250.0%
Neutral1250.0%
Bearish00.0%
1 unmapped firm rating excluded from the percentages.
Bio-Techne Corporation · TECH · FY2025 Q1 · Calendar Q4 2024
Bio-Techne growth broadens, while margin recovery remains a key test
The quarter supports a cautiously constructive view: resilient demand in GMP reagents, diagnostics, and spatial biology broadens the growth base, but margin pressure and uncertain customer funding still need to ease for the outlook to strengthen.
Reported Before market openNASDAQHealthcare
$11.38B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.42
Consensus $0.38
EPS surprise
+10.5%
Reported versus consensus
Reported revenue
$289.5M
Consensus $280.3M
Revenue surprise
+3.3%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+7.5%
Event window
SPY move
-0.3%
Same window
Abnormal move
+7.8%
Stock minus SPY
Volume
3.3×
Versus trailing sessions
Subsequent drift
-0.8%
Up to 20 sessions
TECHSPY benchmark
Ask FN2 about TECH FY2025 Q1
Transcript, numbers and history already loaded
Why did TECH rise 7.5% after beating EPS estimates in FY2025 Q1?What changed in TECH's guidance and outlook in FY2025 Q1?Give me the bull and bear case for TECH after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Growth became more visible across GMP reagents, Diagnostics and Spatial Biology, while management added emphasis on AI-designed proteins and the planned Wilson Wolf ownership transition. Margin pressure remained a central counterweight, but the FY2025 outlook was maintained.
Guidance delta
Maintained: management reaffirmed the FY2025 outlook, including expected margin improvement in the second half.
Key takeaways
- Q1 revenue grew 5% year over year, with organic growth of 4%.
- GMP reagents for cell and gene therapy grew more than 60% year over year.
- Diagnostics and Spatial Biology grew 14%, led by COMET and ExoDx momentum.
- Operating margin faced product-mix and incentive-compensation pressure.
- The investment case depends on new products, diagnostics adoption, and a recovering biotech funding environment.
Management priorities
- Scale GMP reagent demand in cell and gene therapy.
- Expand COMET spatial biology and associated consumables.
- Advance ExoDx and the Asuragen assay portfolio.
- Launch the Leo Simple Western system and broaden the AI-designed protein pipeline.
- Develop Wilson Wolf synergies while planning the remaining-equity acquisition.
Follow TECH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$72.59Current
$49Low
$75.3Average
$106.25High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 21, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Equal Weight | Overweight | Downgrade | Aug 13, 2026 |
| RBC Capital | Sector Perform | Outperform | Downgrade | Jul 9, 2026 |
| TD Cowen | Hold | Buy | Downgrade | Jun 30, 2026 |
| Benchmark | Hold | Buy | Downgrade | Jun 30, 2026 |
| Citigroup | Neutral | Buy | Downgrade | Jun 29, 2026 |
| William Blair | Market Perform | Outperform | Downgrade | Jun 26, 2026 |
| Stephens & Co. | Equal Weight | Overweight | Downgrade | Jun 26, 2026 |
| Baird | Neutral | Neutral | Maintain | Jun 26, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | May 7, 2026 |
| UBS | Buy | Buy | Maintain | Feb 5, 2026 |
| Stifel | Hold | Hold | Maintain | Feb 5, 2026 |
| Argus Research | Buy | Buy | Maintain | Nov 20, 2025 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Jul 11, 2025 |
| Keybanc | Overweight | Downgrade | Apr 9, 2025 | |
| Deutsche Bank | Buy | Buy | Maintain | Apr 18, 2024 |
| SVB Leerink | Outperform | Outperform | Maintain | Feb 3, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 25, 2022 |
| Craig-Hallum | Buy | Buy | Maintain | Feb 3, 2021 |
| Atlantic Equities | Overweight | Overweight | Maintain | Sep 30, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Nov 15, 2019 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Jul 2, 2019 |
| Janney Capital | Buy | Neutral | Upgrade | Jul 2, 2019 |
| Goldman Sachs | Neutral | Neutral | Maintain | Oct 17, 2018 |
| Argus | Buy | Buy | Maintain | Oct 2, 2018 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Apr 29, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $72.6. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Analyst unavailable | $73 | $72.22 | +0.6% | Aug 13, 2026 |
| Stephens | Steven Etoch | $73 | $71.16 | +0.6% | Jun 26, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $73 | $70.7 | +0.6% | Jun 26, 2026 |
| Deutsche Bank | Justin Bowers | $73 | $70.7 | +0.6% | Jun 26, 2026 |
| Leerink Partners | Market Perform | $73 | $70.54 | +0.6% | Jun 25, 2026 |
| Piper Sandler | Analyst unavailable | $65 | $52.5 | -10.5% | Jun 11, 2026 |
| RBC Capital | Analyst unavailable | $62 | $44.74 | -14.6% | May 14, 2026 |
| Evercore ISI | Daniel Markowitz | $50 | $49.26 | -31.1% | May 7, 2026 |
| Stifel Nicolaus | Analyst unavailable | $50 | $47.4 | -31.1% | May 7, 2026 |
| Robert W. Baird | Analyst unavailable | $49 | $47.4 | -32.5% | May 7, 2026 |
| Stifel Nicolaus | Analyst unavailable | $65 | $67.64 | -10.5% | Feb 5, 2026 |
| UBS | Analyst unavailable | $79 | $68.67 | +8.8% | Feb 5, 2026 |
| Robert W. Baird | Analyst unavailable | $70 | $68.67 | -3.6% | Feb 5, 2026 |
| Evercore ISI | Analyst unavailable | $62 | $59.65 | -14.6% | Jan 5, 2026 |
| Deutsche Bank | Justin Bowers | $72 | $59.67 | -0.8% | Dec 12, 2025 |
| Argus Research | Analyst unavailable | $68 | $58.64 | -6.3% | Nov 20, 2025 |
| Evercore ISI | Analyst unavailable | $68 | $58.4 | -6.3% | Nov 6, 2025 |
| RBC Capital | Conor McNamara | $73 | $53.42 | +0.6% | Sep 2, 2025 |
| Evercore ISI | Analyst unavailable | $75 | $62.58 | +3.3% | Mar 17, 2025 |
| Robert W. Baird | Catherine Schulte | $84 | $76.02 | +15.7% | Oct 31, 2024 |
| KeyBanc | Paul Knight | $80 | $76.02 | +10.2% | Oct 30, 2024 |
| Scotiabank | Sung Ji Nam | $83 | $74.19 | +14.3% | Aug 16, 2024 |
| Deutsche Bank | Analyst unavailable | $100 | $86.98 | +37.8% | Dec 14, 2022 |
| Citigroup | Analyst unavailable | $100 | $80.73 | +37.8% | Dec 12, 2022 |
| RBC Capital | Analyst unavailable | $89 | $80.67 | +22.6% | Dec 7, 2022 |
| Stephens | Analyst unavailable | $105 | $82.44 | +44.6% | Dec 5, 2022 |
| KeyBanc | Paul Knight | $125 | $98.96 | +72.2% | May 5, 2022 |
| Wells Fargo | Analyst unavailable | $92.5 | $100.75 | +27.4% | Apr 25, 2022 |
| Citigroup | Patrick B Donnelly | $106.25 | $102.45 | +46.4% | May 6, 2021 |
Track every rating change on TECH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.…
Historical context
All TECH earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ABT Abbott Laboratories | FY2026 Q3 · Calendar Q4 2026 | — | -3.6% | Abbott lowers revenue outlook while advancing nutrition spin-off |
| DHR Danaher Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +2.9% | Danaher raises EPS outlook as Q3 growth reaches 5.5% |
| TMO Thermo Fisher Scientific Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +2.5% | Thermo Fisher raises 2026 guidance as pharma services and AI support growth |
| ELV Elevance Health Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -0.2% | Elevance Health raises 2026 EPS outlook as Medicaid and Carelon improve |
| ISRG Intuitive Surgical, Inc. | FY2026 Q3 · Calendar Q4 2026 | +13.2% | -3.6% | Intuitive Surgical: Strong Q3 growth, with pricing and policy risks ahead |
Latest beats and misses
Who reports nextBeat on EPS
- NLY-PFFY2026 Q3 · October 20, 2026+3.6% EPS— move
- NLY-PGFY2026 Q3 · October 20, 2026+3.6% EPS— move
- NLYFY2026 Q3 · October 20, 2026+3.6% EPS-0.6% move
- CBFY2026 Q3 · October 20, 2026+12.8% EPS-0.4% move
- ISRGFY2026 Q3 · October 20, 2026+13.2% EPS-3.6% move
- SPCXFY2026 Q3 · October 20, 2026+160.0% EPS-0.1% move
Missed on EPS
- PACFY2026 Q3 · October 20, 2026-2.2% EPS+7.1% move
- AGNCZFY2026 Q3 · October 19, 2026-0.6% EPS+0.3% move
- AGNCLFY2026 Q3 · October 19, 2026-0.6% EPS-0.3% move
- AGNCOFY2026 Q3 · October 19, 2026-0.6% EPS+0.3% move
- AGNCPFY2026 Q3 · October 19, 2026-0.6% EPS0.0% move
- AGNCMFY2026 Q3 · October 19, 2026-0.6% EPS-0.3% move
Get the TECH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-21T15:30:44.074853+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-21T15:30:44.071541+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-21. For educational purposes only; not investment advice.